Introduction
•
SCLC
is a:
–
high-grade
neuroendocrine tumour
–
10-15% of lung cancer
p.
–
very
large number of genetic alterations
–
associated with a
poor OS:
5-y 7%
–
limited progress
in the treatment over the past
3 decades
•
Over the past 5 years
:
–
advances
in our
understanding
of multiple aspects of its
biology
–
development of
new therapies
currently under
clinical
investigation